Literature DB >> 25582198

Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.

Qian Zhang1, Qingchao Tang1, Dandan Qin2, Lei Yu1, Rui Huang1, Guixiang Lv3, Zhaoxia Zou3, Xiao-chen Jiang3, Chendan Zou3, Wei Liu3, Jing Luo3, Zhixun Zhao1, Shan Muhammad1, Guiyu Wang1, Ying-gang Chen1, Xishan Wang4.   

Abstract

MicroRNAs (miRNAs) are dysregulated in many types of malignant diseases, including colorectal cancer. miRNA 30a (miR-30a) is a member of the miR-30 family and has been implicated in many types of cancers. In this study, we determined the expression of miR-30a in human colon cancer tissues and cell lines. miR-30a was found to be significantly downregulated in both the tissues and cell lines. Furthermore, overexpression of miR-30a inhibited, while silencing of miR-30a promoted, cell proliferation, migration, and invasion in vitro. Consistently, stable overexpression of miR-30a suppressed the growth of colon cancer cell xenografts in vivo. Moreover, bioinformatic algorithms and luciferase reporter assays revealed that insulin receptor substrate 2 (IRS2) is a direct target of miR-30a. Further functional studies suggested that repression of IRS2 by miR-30a partially mediated the tumor suppressor effect of miR-30a. In addition, miR-30a inhibited constitutive phosphorylation of Akt by targeting IRS2. Additionally, clinicopathological analysis indicated that miR-30a has an inverse correlation with the staging in patients with colon cancer. Taken together, our study provides the first evidence that miR-30a suppressed colon cancer cell growth through inhibition of IRS2. Thus, miR-30a might serve as a promising therapeutic strategy for colon cancer treatment.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25582198      PMCID: PMC4333091          DOI: 10.1128/MCB.01242-14

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

1.  MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer.

Authors:  Regalla Kumarswamy; Giridhar Mudduluru; Paolo Ceppi; Santoshi Muppala; Miroslaw Kozlowski; Jacek Niklinski; Mauro Papotti; Heike Allgayer
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

2.  Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

Authors:  Na Liu; Nian-Yong Chen; Rui-Xue Cui; Wen-Fei Li; Yan Li; Rong-Rong Wei; Mei-Yin Zhang; Ying Sun; Bi-Jun Huang; Mo Chen; Qing-Mei He; Ning Jiang; Lei Chen; William C S Cho; Jing-Ping Yun; Jing Zeng; Li-Zhi Liu; Li Li; Ying Guo; Hui-Yun Wang; Jun Ma
Journal:  Lancet Oncol       Date:  2012-05-03       Impact factor: 41.316

3.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Authors:  Zhibin Hu; Xi Chen; Yang Zhao; Tian Tian; Guangfu Jin; Yongqian Shu; Yijiang Chen; Lin Xu; Ke Zen; Chenyu Zhang; Hongbing Shen
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

4.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Authors:  Michelle A Blaskovich; Jiazhi Sun; Alan Cantor; James Turkson; Richard Jove; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

Review 5.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

6.  Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells.

Authors:  C Quintavalle; E Donnarumma; M Iaboni; G Roscigno; M Garofalo; G Romano; D Fiore; P De Marinis; C M Croce; G Condorelli
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

7.  Breast tumor-associated osteoblast-derived CXCL5 increases cancer progression by ERK/MSK1/Elk-1/snail signaling pathway.

Authors:  Y-L Hsu; M-F Hou; P-L Kuo; Y-F Huang; E-M Tsai
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

8.  Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types.

Authors:  Eric S Martin; Giovanni Tonon; Raktim Sinha; Yonghong Xiao; Bin Feng; Alec C Kimmelman; Alexei Protopopov; Elena Ivanova; Cameron Brennan; Kate Montgomery; Raju Kucherlapati; Gerald Bailey; Mark Redston; Lynda Chin; Ronald A DePinho
Journal:  Cancer Res       Date:  2007-11-15       Impact factor: 12.701

9.  MicroRNA-mediated regulation of Ubc9 expression in cancer cells.

Authors:  Fangting Wu; Shuomin Zhu; Yanna Ding; William T Beck; Yin-Yuan Mo
Journal:  Clin Cancer Res       Date:  2009-02-17       Impact factor: 12.531

10.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Authors:  R Visone; P Pallante; A Vecchione; R Cirombella; M Ferracin; A Ferraro; S Volinia; S Coluzzi; V Leone; E Borbone; C-G Liu; F Petrocca; G Troncone; G A Calin; A Scarpa; C Colato; G Tallini; M Santoro; C M Croce; A Fusco
Journal:  Oncogene       Date:  2007-06-11       Impact factor: 9.867

View more
  28 in total

1.  BMP9-induced osteogenic differentiation is partially inhibited by miR-30a in the mesenchymal stem cell line C3H10T1/2.

Authors:  Ruyi Zhang; Yaguang Weng; Baolin Li; Yingjiu Jiang; Shujuan Yan; Fang He; Xiaoqing Chen; Fang Deng; Jing Wang; Qiong Shi
Journal:  J Mol Histol       Date:  2015-07-24       Impact factor: 2.611

2.  MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1.

Authors:  Hongxing Shen; Chuan Xing; Kaisa Cui; Yunxiao Li; Jinxiang Zhang; Runlei Du; Xiaodong Zhang; Youjun Li
Journal:  Cell Death Differ       Date:  2017-05-05       Impact factor: 15.828

3.  MicroRNA-30a-5p (miR-30a) regulates cell motility and EMT by directly targeting oncogenic TM4SF1 in colorectal cancer.

Authors:  Y R Park; S L Kim; M R Lee; S Y Seo; J H Lee; S H Kim; I H Kim; S O Lee; S T Lee; Sang Wook Kim
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-20       Impact factor: 4.553

Review 4.  An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach.

Authors:  Wenhao Weng; Junlan Feng; Huanlong Qin; Yanlei Ma; Ajay Goel
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

5.  The IL-1β/AP-1/miR-30a/ADAMTS-5 axis regulates cartilage matrix degradation in human osteoarthritis.

Authors:  Quanbo Ji; Xiaojie Xu; Qiang Zhang; Lei Kang; Yameng Xu; Ke Zhang; Ling Li; Yingchun Liang; Tian Hong; Qinong Ye; Yan Wang
Journal:  J Mol Med (Berl)       Date:  2016-04-11       Impact factor: 4.599

6.  microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2.

Authors:  Su Dong; Xianying Meng; Shuai Xue; Zewen Yan; Peiyou Ren; Jia Liu
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

7.  MiR-30a regulates the proliferation, migration, and invasion of human osteosarcoma by targeting Runx2.

Authors:  Ruyi Zhang; Shujuan Yan; Jing Wang; Fang Deng; Yangliu Guo; Ya Li; Mengtian Fan; Qilin Song; Hongxia Liu; Yaguang Weng; Qiong Shi
Journal:  Tumour Biol       Date:  2015-10-09

8.  MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression.

Authors:  Bairong Xia; Huiyan Li; Shanshan Yang; Tianbo Liu; Ge Lou
Journal:  Tumour Biol       Date:  2016-01-14

9.  Overexpression of miR-30a in lung adenocarcinoma A549 cell line inhibits migration and invasion via targeting EYA2.

Authors:  Yuncang Yuan; Shangyong Zheng; Qian Li; Xudong Xiang; Tangxin Gao; Pengzhan Ran; Lijuan Sun; Qionglin Huang; Fei Xie; Jing Du; Chunjie Xiao
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-01       Impact factor: 3.848

10.  Downregulation of miR-30a is associated with proliferation and invasion via targeting MEF2D in cervical cancer.

Authors:  Jing Zhao; Bo Li; Chuqiang Shu; Yun Ma; Yingping Gong
Journal:  Oncol Lett       Date:  2017-10-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.